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Parathyroid hormone (PTH) related peptide
(PTHrP) and the PTH/PTHrP receptor (PTH/
PTHrP-R) show prominent cutaneous expression,
where this signaling system may exert important
paracrine and/or autocrine functions, such as in hair
growth control. Chemotherapy-induced alopecia ±
one of the fundamental unsolved problems of clinical
oncology ± is driven in part by de®ned abnormalities
in hair follicle cycling. We have therefore explored
the therapeutic potential of a PTH/PTHrP-R agonist
and two PTH/PTHrP-R antagonists in a mouse
model of cyclophosphamide-induced alopecia.
Intraperitoneal administration of the agonist PTH(1±
34) or the antagonists PTH(7±34) and PTHrP(7±34)
signi®cantly altered the follicular response to cyclo-
phosphamide in vivo. PTH(7±34) and PTHrP(7±34)
shifted it towards a mild form of ``dystrophic ana-
gen'', associated with a signi®cant reduction in
apoptotic (TUNEL+) hair bulb cells, thus mitigating
the degree of follicle damage and retarding the onset
of cyclophosphamide-induced alopecia. PTH(1±34),
in contrast, forced hair follicles into ``dystrophic
catagen'', associated with enhanced intrafollicular
apoptosis. We had previously shown that an induced
shift in the follicular damage-response towards ``dys-
trophic catagen'' mitigates cyclophosphamide-
induced alopecia, whereas a shift towards ``dys-
trophic catagen'' initially enhanced the hair loss, yet
subsequently promoted accelerated hair follicle
recovery. Therefore, this study in an established ani-
mal model of chemotherapy-induced alopecia,
which closely mimics human chemotherapy-induced
alopecia, strongly encourages the exploration of
PTH/PTHrP-R agonists and antagonists as novel
therapeutic agents in chemotherapy-induced alope-
cia. Key words: cancer therapy/hair loss/parathyroid
hormone/parathyroid hormone related peptide. J Invest
Dermatol 117:173±178, 2001
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arathyroid hormone related peptide (PTHrP), the major
causative agent of malignancy-associated hypercalcemia,
plays a role in regulating keratinocyte proliferation and
differentiation (Merendino et al, 1986; Merryman et al,
1993; Holick et al, 1994; Kaiser et al, 1994;
Wysolmerski et al, 1994; Kremer et al, 1996). In human and rat
skin, PTHrP is produced by keratinocytes (Danks et al, 1989; Lee
et al, 1995; Shin et al, 1997), whereas the PTH/PTHrP receptor
(PTH/PTHrP-R) is expressed by ®broblasts (Hana®n et al, 1995;
Lee et al, 1995). PTHrP synthesis and release from keratinocytes are
enhanced under conditions in which keratinocyte differentiation is
induced, e.g., by ®broblast-derived growth factors (Kremer et al,
1991; Grone et al, 1996). PTH/PTHrP-R agonists stimulate
insulin-like growth factor I production by ®broblasts (Wu et al,
1987; Shin et al, 1997), which acts as a cell cycle progression factor
in keratinocytes (Tsuboi et al, 1992; Ristow, 1996; Vogt et al,
1997). PTHrP may thus be involved in dermo-epidermal
(epithelial±mesenchymal) cross-talk, acting as a paracrine factor,
which promotes keratinocyte differentiation and regulates prolif-
eration (Merryman et al, 1993; Holick et al, 1994; Kaiser et al,
1994). PTH/PTHrP-R agonists can inhibit proliferation and can
stimulate differentiation of keratinocytes (Holick et al, 1994; Kaiser
et al, 1994), probably via an additional PTH/PTHrP-R subtype
that remains to be identi®ed (Henderson et al, 1992; Orloff et al,
1992, 1995).
Increasing evidence suggests that PTH/PTHrP-R-mediated
signaling is also involved in hair growth control, speci®cally in
the control of hair follicle cycling (Schilli et al, 1997). Human
keratin 14 promoter-PTHrP transgenic mice show a retardation of
or even lack hair follicle initiation (Wysolmerski et al, 1994). When
the synthetic PTH/PTHrP-R antagonist PTH(7±34) was given
intraperitoneally to hairless mice, it increased hair growth (Holick
et al, 1994). PTH(7±34) also accelerated anagen development in
infantile C57BL/6 mice with normal hair growth patterns, and
inhibited spontaneous hair follicle regression (catagen) in adolescent
C57BL/6 mice (Schilli et al, 1997).
As abnormalities of hair follicle cycling are at the basis of
most clinically important human hair growth disorders (Paus et al,
1996; Paus and Cotsarelis, 1999), these hair-cycle-modulatory
properties of a PTH/PTHrP-R antagonist encouraged us to
explore both antagonists and an agonist of the PTH/PTHrP-R in
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the chemotherapy-induced alopecia C57BL/6 mouse model for
hair research (Paus et al, 1990, 1994a, b). Speci®cally, we were
interested in determining whether PTH/PTHrP-R agonist or
antagonist might be exploitable to manipulate chemotherapy-
induced alopecia in these mice, which had been shown to closely
mimic human chemotherapy-induced alopecia (Paus et al, 1994a,
1996; Slominski et al, 1996).
Chemotherapy-induced alopecia remains one of the chief
unresolved clinical problems in oncologic practice, and a
substantial source of patient suffering from the psychologically
devastating effects of sudden and often dramatic hair loss. We
therefore reasoned that the hair-cycle-modulatory properties of
PTH/PTHrP-R-mediated signaling might offer a novel tool for
therapeutic hair growth manipulation in patients with chemo-
therapy-induced alopecia, who show striking abnormality of hair
follicle cycling (Paus et al, 1994a, 1996; Paus and Cotsarelis,
1999). Using this mouse model of chemotherapy-induced
alopecia, we had previously shown that the onset and degree
of alopecia and the hair regrowth after intraperitoneal treatment
with cyclophosphamide (CYP) re¯ect varying degrees of follicle
damage (Paus et al, 1994a; Maurer et al, 1997a), which can best
be judged from the degree of pigmentary disturbances (``dys-
trophy'') in the hair follicle (Slominski et al, 1996) and the
massively upregulated apoptosis of hair bulb keratinocytes as a
consequence of chemotherapy (Lindner et al, 1997).
Chemotherapy-damaged anagen hair follicles respond in two
distinct patterns. The so-called dystrophic anagen pathway
results in a less severe degree of follicle damage that actually
leads to a prolongation of the normal duration of anagen, but is
associated with a relatively slow, incomplete follicle recovery
and regrowth of normal hair shafts. The so-called dystrophic
catagen pathway results in maximal follicle damage, yet also
allows the fastest recovery from chemotherapy-induced alopecia
and the fastest regrowth of normally pigmented hair, because
the damaged anagen follicle is immediately deconstructed to
permit the generation of a new, normally functioning anagen
follicle (Paus et al, 1994a, 1996).
We therefore hypothesized that a PTH/PTHrP-R agonist
might favor the dystrophic catagen pathway by upregulating
follicle keratinocyte differentiation and/or apoptosis, whereas a
PTH/PTHrP-R antagonist might favor the dystrophic anagen
pathway by stimulating hair follicle keratinocyte proliferation,
possibly as a consequence of antagonizing the inhibitory effects
of local PTH/PTHrP on keratinocyte proliferation. This would
have important conceptual implications for the design of new
therapeutic strategies to counteract human chemotherapy-
induced alopecia (either by mitigating the degree of alopecia
via favoring dystrophic anagen, or by accelerating normal hair
regrowth via stimulation of dystrophic catagen). In addition, this
would provide additional insights into the biologic signi®cance
of PTH/PTHrP-R-mediated signaling in hair follicle biology.
Therefore, we investigated the effects of parenteral administra-
tion of a PTH/PTHrP-R agonist [PTH(1±34)] and two PTH/
PTHrP-R antagonists [PTH(7±34) and PTHrP(7±34)] on
CYP-induced alopecia, hair follicle cycling, and keratinocyte
apoptosis in C57BL/6 mice after CYP treatment.
MATERIALS AND METHODS
Mice Six- to 9-wk-old, syngeneic, female C57BL/6 mice in the
telogen stage of the hair cycle were purchased from Jackson Laboratories
(Bar Harbour, ME). The mice were housed in community cages with 12
h light periods at animal facilities in the Boston University Medical
Center, and were fed water and mouse chow ad libitum.
PTH and PTHrP analogs The PTH(1±34) human [PTH(1±34)],
PTHrP(1±34) amide human [PTHrP(1±34)], PTHrP(7±34) amide human
[PTHrP(7±34)] and Nle8,Tyr34-PTH(7±34) amide bovine [PTH(7±34)]
were purchased from Bachem California (Torrance, CA).
Hair cycle induction and chemotherapy-induced alopecia
model Anagen was induced in the back skin of mice in the telogen
phase of the hair cycle (identi®ed by their homogeneously pink back
skin color) by depilation. Depilation was accomplished by applying a 1:1
melted wax/rosin mixture under anesthesia, as described previously (Paus
et al, 1990). After hardening, the wax/rosin mixture was peeled off the
skin, plucking out all telogen hair shafts, which induces the predictable
and highly synchronized development of anagen follicles that are
morphologically indistinguishable from spontaneous anagen follicles
(Chase, 1954; Slominski and Paus, 1993). On day 9 post depilation
(p.d.), i.e., when all hair follicles in the depilated area had reached early
anagen VI, a single dose of CYP (120 mg per g bodyweight; obtained
from Novartis, Basel, Switzerland) was administered intraperitoneally,
which induces hair follicle dystrophy in all anagen hair follicles as
described previously (Paus et al, 1994a, 1996; Maurer et al, 1997a).
Pharmacologic manipulation of chemotherapy-induced alopecia
by PTH(7±34) or PTHrP(7±34) PTH(7±34), PTHrP(7±34), or
PTH(1±34) (50 mg per kg bodyweight) was injected twice (at 8:00 a.m.
and 12:00 p.m. Eastern Standard Time) intraperitoneally on days 6, 7, 8,
10, 12, and 13 p.d. to a total of 23±29 mice per group in three separate
experiments that yielded highly comparable results. Control mice
received the vehicle or distilled H2O and CYP only. On day 9 p.d. mice
received three injections once every 2 h of one of the PTH/PTHrP
analogs, and a single additional injection of CYP (120 mg per kg
bodyweight) 30 min after the second injection of the PTH/PTHrP
analog (Table I). All tested substances were dissolved in deionized H2O,
aliquoted, lyophilized in glass tubes, and stored at ±80°C until needed, to
guarantee peptide stability. Immediately prior to use, aliquoted portions
were dissolved in a total volume of deionized H2O and injected
intraperitoneally into each test mouse.
Mice were killed by cervical dislocation on days 13, 14, or 30 p.d.
Back skin from the depilated skin area (reaching from the midline
between the ears to the insertion of the tail) was harvested perpendicular
to the paravertebral line in order to obtain longitudinal hair follicle
sections. Skin samples were immediately frozen in liquid nitrogen and
embedded as described (Paus et al, 1994a; Lindner et al, 1997; Maurer
et al, 1997a).
Evaluation of chemotherapy-induced alopecia After the CYP
injection on day 9 p.d., the back skin of test and control animals was
examined daily for signs of alopecia. In one of the three separate
experiments, six mice out of each group were kept alive until day 30
Table I. Treatment schedules for PTH and PTHrP analogs and CYP in depilated C57BL/6 mice
Tested compound Conc. tested Days of application
Photodocumentation/
macroscopic evaluation Day of harvesting
PTH(7±34) 50 mg per kg bodyweight 6 7 8 9 10 11 12 7 8 9 1 1 1 1 1 13, 14 or 30
2x 2x 2x 3x 2x 2x 2x 0 1 2 3 4
PTHrP(7±34) 50 mg per kg bodyweight 6 7 8 9 10 12 1 7 8 9 1 1 1 1 1 13, 14 or 30
2x 2x 2x 3x 2x 2x 2x 0 1 2 3 4
PTH(1±34) 50 mg per kg bodyweight 6 7 8 9 10 12 13 7 8 9 1 1 1 1 1 13, 14 or 30
2x 2x 2x 3x 2x 2x 2x 0 1 2 3 4
CYP 120 mg per kg bodyweight 9
1x
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p.d. so as to follow the course of alopecia and hair regrowth after
chemotherapy-induced alopecia (Paus et al, 1994). Mice were
photographed under standardized conditions up to twice daily from day
7. The macroscopic data were derived from an analysis of mice
photographed on day 14 p.d. Visual quanti®cation of hair loss was
performed on photomicrographs taken daily. The length of the total
depilated area and the length of the back skin in anagen (black skin,
growing hair), as well as the length of the back skin with signs of
alopecia or total hair loss were measured in centimeters. The ratio of
anagen skin to total back skin for each mouse was determined. These
numbers were expressed in percent and pooled for each group to allow
for statistical analysis. These macroscopic observations were correlated by
quantitative histomorphometry. Hair cycle staging was performed on
10 mm skin sections at 2003 magni®cation under a Zeiss Axioscope
microscope on test or control skin of all mice, and harvested on days 13
or 14 p.d., as previously described (Paus et al, 1994a; Maurer et al,
1997a, b). In short, a minimum of 20 randomly chosen hair follicles
from three skin regions (neck, mid, tail) of the mouse, comprising an
average mixture of all hair cycle stages present in the paravertebral
depilated skin area (i.e., a minimum of 360 hair follicles per group and
day p.d.), was evaluated, and the percent of anagen VI, early catagen,
mid catagen, and late catagen hair follicles as well as the mean hair cycle
stage (hair cycle score [HCS]: anagen VI, 100; early catagen, 200; mid
catagen, 300; late catagen, 400) per mouse was calculated as described
previously (Paus et al, 1994a; Maurer et al, 1997a). Data were pooled,
and the means 6 SEM were calculated. p-values were determined by
the Kruskal±Wallis test for unpaired samples.
Apoptosis assay To evaluate the number of apoptotic cells in the hair
follicle epithelium, we used a commercially available ¯uorescent TUNEL
kit (ApopTag, Oncor) in combination with counterstaining by Hoechst
33342 dye (Sigma) as described previously (Lindner et al, 1997).
Apoptotic cells were identi®ed as TUNEL+ cells with shrunken,
intensively Hoechst 33342-stained nuclei, and fragmented chromatin. As
there is prominent, spontaneous apoptosis in thymocytes of infantile
mice, the same procedure was carried out on thymus cryosections of 4-
wk-old mice as positive controls, which con®rmed the sensitivity and
speci®city of our TUNEL technique (Lindner et al, 1997).
Negative controls for the TUNEL staining were made by omitting
terminal desoxynucleotidyl transferase. For quantitative histomorphome-
try, TUNEL+ cells were counted in the hair bulb and epithelial strand
(Bulfone-Paus et al, 1997; Lindner et al, 1998) of at least 10 randomly
chosen hair follicles from three skin regions (neck, mid, tail) of the
mouse, comprising an average mixture of all hair cycle stages present in
the paravertebral depilated skin area derived from three randomly
selected mice per group, harvested on day 13 or day 14 p.d. (i.e., more
than 90 hair follicles were studied for each group and day p.d.). Data
were pooled, and the means 6 SEM were calculated. p-values were
determined by the Kruskal±Wallis test for unpaired samples.
RESULTS
CYP-induced alopecia The mice that received the CYP
showed severe hair loss (Fig 1A). Signs of CYP-induced alopecia
were detected ®rst in the neck region of the control animals on day
12 p.d., when hair shafts became easily pluckable in the neck
region, and proceeded towards the tail over the entire depilated
skin area. Alopecia in the control animals extended from the neck
to the mid-back region between days 13 and 14 p.d. (Fig 1A).
Histologically, this was accompanied by the induction of dystrophic
anagen and dystrophic catagen (Fig 1B, C) as previously described
(Paus et al, 1994a; Slominski et al, 1996).
Effect of PTHrP(7±34) and PTH(7±34) on retarding the
onset of CYP-induced alopecia Administration of PTH(7±34)
or PTHrP(7±34) intraperitoneally signi®cantly retarded the
development of CYP-induced alopecia by 48% 6 4% and
81% 6 4% (mean 6 SEM; p < 0.01), respectively (Fig 2). Much
less hair was lost in mice treated with PTHrP(7±34) (Fig 1D) and
PTH(7±34) (data not shown) than in those treated with vehicle
alone (Fig 1A) and the hair follicles were more robust and less
dystrophic (Fig 1E, F) compared with the control animals
(Fig 1B, C). The average hair cycle score in CYP-treated
control animals demonstrated that the hair follicles were
transformed from early catagen transgressing to mid-catagen,
whereas mice treated with PTH(7±34) and PTHrP(7±34)
maintained a hair cycle score around or below 200, which
indicated that most of the CYP-damaged hair follicles had
remained in anagen VI and early catagen (Fig 2A).
These differences became obvious when the percentage of
anagen VI follicles in the skin of test and control animals was
compared by quantitative histomorphometry. In control mice
treated with CYP and vehicle, less than 20% of the hair follicles
over the whole back skin remained in anagen VI on day 13 p.d.
(Fig 2B) and this number declined further on day 14 (data not
shown). In contrast, between 30% and 40% of all back skin hair
follicles were in anagen VI on days 13 and 14 for the mice treated
with PTHrP(7±34) (Fig 2B) or PTH(7±34) (data not shown).
Thus, the PTH/PTHrP-R antagonists markedly inhibited CYP-
induced dystrophic damage of the hair follicle.
Figure 1. Development of alopecia in CYP-
treated mice. Representative pictures of mice
treated with CYP on day 14 d.p. and control
vehicle (A) or PTHrP(7±34) (D) and histologic
sections from a control mouse (B, C) and a
PTHrP(7±34)-treated mouse (E, F). All
photographs shown were taken prior to harvesting
on day 14 p.d. Loose hair shafts were removed
prior to photography by stroking the back skin of
each mouse 10 times from the tail to the neck
followed by 10 strokes from the neck to the tail
with the ¯at right hand covered by a plastic glove.
(A) Animals treated with CYP (120 mg per kg
bodyweight) only displayed 80% hair loss on
average. The irregular orientation of small groups
of hair shafts in the upper back region occurs
when hair shafts are easily pluckable. (D) Animals
treated with CYP and PTHrP(7±34) (50 mg per
kg bodyweight) displayed visible hair loss over
approximately 30% of their depilated skin area.
(C) and (F) are higher magni®cations of hair
follicles in (B) and (E), respectively.
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Previously, it was shown that, when mice were evaluated for hair
follicle recovery after CYP injection, drugs that favored the
dystrophic anagen pathway led to relatively slow and incomplete
follicle recovery with retarded regrowth of normal pigmented hair
shafts (Fig 3B). Mice treated with PTH(7±34) (Fig 3C) and
PTHrP(7±34) (data not shown), however, had accelerated hair
regrowth.
Consistent with the observation that PTH/PTHrP antagonists
inhibited chemotherapy-induced dystrophic hair follicle progres-
sion, our evaluation of apoptotic TUNEL+ cells in the hair bulb on
day 13 revealed a 26% 6 3% (mean 6 SEM; p < 0.01) reduction in
the animals treated with the PTH/PTHrP-R antagonist PTHrP
(7±34) compared with the control mice treated only with CYP and
control vehicle.
Effect of PTH(1±34) on accelerating CYP-induced
alopecia It was hypothesized that as PTH(1±34) enhanced hair
follicle keratinocyte maturation and differentiation, it would
accelerate the hair cycle and therefore make hair follicles more
sensitive to chemotherapy. Macroscopic evaluation revealed that
the hair loss in mice treated with PTH(1±34) was signi®cantly more
(160% 6 4%; mean 6 SEM; p < 0.01) than in the control group
(Fig 4). Quantitative histomorphometry revealed that PTH(1±34)
signi®cantly augmented CYP-induced dystrophic catagen
progression as predicted. An analysis of the hair cycle score
revealed that animals receiving PTH(1±34) had a score of 250±275,
which indicated that the hair cycle progression was accelerated
towards late catagen (Fig 5A). Therefore, treatment with PTH(1±
34) signi®cantly accelerated the hair cycle progression towards
completion of catagen development. By day 14 p.d. less than 2% of
the hair follicles were in anagen VI in the PTH(1±34)-treated
animals compared with 15% in the control mice (Fig 5B), and 60%
of all hair follicles in the PTH(1±34) animals were in mid and late
catagen compared with 35% in the control group (Fig 5C).
Effect of PTH(1±34) on hair regrowth If the hair follicle
keratinocytes could be made to be more sensitive to CYP by
accelerating differentiation, this could lead to a more rapid
recovery. Mice that received PTH(1±34) showed faster regrowth
of a normally pigmented fur coat than the control group treated
with CYP and vehicle alone (Fig 4D, E).
An evaluation of the number of apoptotic cells in the hair follicle
bulb from animals treated with PTH(1±34) showed a markedly
increased number (120% 6 4%, mean 6 SEM; p < 0.001)
compared with the control animals, consistent with the hypothesis.
CONCLUSION
Using the mouse model of chemotherapy-induced alopecia that
closely mimics human chemotherapy-induced alopecia, we have
demonstrated for the ®rst time that PTH/PTHrP-R agonist
PTH(1±34) and the PTH/PTHrP-R antagonists PTH(7±34) and
PTHrP(7±34) can effectively manipulate the hair follicle response
to CYP-induced damage. We have demonstrated that (i) PTH(7±
Figure 3. C57BL/6 mice that received CYP
and either vehicle (B), or PTH(7±34) (C) 30 d
p.d. (A) Representative mice that did not receive
CYP. Note that the mice treated with PTH(7±34)
or PTHrP(7±34) had more rapid hair growth
recovery compared with the mouse that received
vehicle alone.
Figure 2. Modulation of CYP-induced alopecia by PTH/PTHrP
receptor antagonists, on day 13 after anagen induction by
depilation. The mean hair cycle stage (HCS: anagen VI, 100; early
catagen, 200; mid catagen, 300; late catagen, 400), as well as the
percentage of anagen VI, early catagen, mid catagen, and late catagen
hair follicles, were calculated from a minimum of 60 hair follicles per
mouse. Data were pooled and the means 6 SEM were calculated. p-
values were determined by the Krustal±Wallis test for unpaired samples
(*p-value < 0.05, **p-value < 0.01). (A) The HCS in CYP-treated
control animals averaged 220, corresponding to early to mid catagen.
Mice treated with PTHrP(7±34) or PTH(7±34) showed scores below
200, which is representative for the transition from anagen to early
catagen. (B) Less than 20% of the hair follicles remain in anagen in
control animals. In contrast, PTH(7±34)- and PTHrP(7±34)-treated mice
maintain around 35% of their follicles in anagen VI.
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34) and PTHrP(7±34) signi®cantly retarded the visible occurrence
of CYP-induced alopecia; (ii) PTH(7±34) and PTHrP(7±34)
mitigated the tempo of CYP-induced dystrophic catagen progres-
sion; (iii) PTHrP(7±34) and PTH(7±34) reduced intrafollicular
apoptosis induced by CYP; (iv) PTH(7±34) and PTHrP(7±34)
accelerated hair regrowth; (v) PTH(1±34) signi®cantly augmented
CYP-induced dystrophic catagen progression; (vi) PTH(1±34)
augmented intrafollicular apoptosis induced by CYP; (vii) PTH(1±
34) accelerated hair regrowth.
The effects of the PTH and PTHrP analogs on chemotherapy-
induced hair loss were not related to their calciotropic activities as
the serum calcium values in the control group were no different
than in the PTH and PTHrP analog treated groups. None of the
animals who received the PTH/PTHrP analogs had soft tissue
calci®cations or any other pathology on visual inspection.
Other attempts to in¯uence the course of the development of
chemotherapy-induced alopecia have concentrated on local
treatment, e.g., with cooling, N-acetylcystein, 1,25-dihydroxyvi-
tamin D3, cyclosporine A, or minoxidil, with varying results
(Jimenez et al, 1992; Hussein, 1995; Hussein et al, 1995; Chen et al,
1998; Hidalgo et al, 1999; Katsimbri et al, 2000). Many of these
studies looked at the chemoprotective effects on chemotherapy-
induced alopecia in the newborn rat model or in the mouse and
rarely investigated the simultaneous effect on tumor growth
(Jimenez et al, 1992; Paus et al, 1994a; Hussein, 1995; Hussein
et al, 1995). Interestingly, topical 1,25-dihydroxyvitamin D3 treat-
ment protected from cyclosporine-induced alopecia but not from
cyclosporine toxicity for chloroleukemia cells or EMT-6 murine
mammary tumor cells (Jimenez et al, 1995; Chen et al, 1998).
Taking these observations into account, additional studies with
PTH/PTHrP-R agonists and antagonists will be needed to evaluate
their utility for local treatment and whether they have any effects
on tumor growth.
It is interesting that we observed better hair regrowth after
chemotherapy in the animals that received PTH(1±34). This was
not unexpected. Previously published observations on hair loss
during and hair recovery after chemotherapy (Paus et al, 1994a) had
shown that follicles that respond to chemotherapy by going into
dystrophic anagen will retain their hair shaft longer but have greater
dif®culty to recover than follicles that go into dystrophic catagen.
These effects seem to re¯ect a response mechanism of the hair
follicle to damage (cf. Paus et al, 1996), depending on the degree
and acuteness of damage to the follicle.
These results suggest that the inhibitory/disinhibitory properties
of PTH/PTHrP-R agonists and antagonists not only may be useful
for regulating hair follicle cycling under physiologic conditions,
but, under pathologic conditions such as CYP-induced alopecia,
may be used and manipulated to either prevent chemotherapy-
induced alopecia or accelerate regrowth. It may be contemplated,
for example, that initially during chemotherapy a PTH/PTHrP-R
antagonist be given to prevent the acceleration of the hair cycle,
thereby decreasing the sensitivity of the hair follicle cells to CYP.
After completion of the chemotherapy, however, a PTH/PTHrP-
R agonist could be given which would accelerate the hair cycle and
thereby stimulate regrowth.
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upper back region; this occurs when hair shafts are easily pluckable and are to be shed soon. (B) Animals treated with CYP and PTH(1±34) (50 mg per
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Figure 5. Modulation of CYP-induced alopecia by PTH/PTHrP
receptor agonist: day 14 after anagen induction by depilation.
The mean hair cycle stage (HCS: anagen VI, 100; early catagen, 200;
mid catagen, 300; late catagen, 400) as well as the percentage of anagen
VI, early catagen, mid catagen, and late catagen hair follicles were
calculated from a minimum of 60 hair follicles per mouse. Data were
pooled and the means 6 SEM were calculated. p-values were
determined by the Krustal±Wallis test for unpaired samples (*p-value
< 0.05, **p-value < 0.01, ***p-value < 0.001). (A) The HCS in CYP-
treated control animals averaged close to 240 score points, corresponding
to early to mid catagen. Mice treated with PTH(1±34) showed
signi®cantly increased scores close to 270, indicating the rapid
progression towards mid and late catagen. (B) Less than 20% of the hair
follicles remain in anagen VI in control animals but in mice treated with
PTH(1±34) these follicles have almost disappeared. (C) In control
animals around 35% of all hair follicles have reached mid and late
catagen, whereas treatment with PTH(1±34) caused signi®cant
augmentation of hair cycle progression, with around 60% of all hair
follicles in mid and late catagen.
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